Biostock interview: Anders Weilandt on Chordate’s progress on the German market

Biostock interviews Chordate Medical CEO Anders Weilandt about Chordate’s participation at the prominent pain congress Deutsche Schmerzkongress in Mannheim, and why Germany is an important market for the company.

“The market introduction in Germany is going according to plan, and it is now a matter of getting a small number of clinics that want to get started. At the same time, we are working on various solutions so that the patient will eventually be able to receive insurance compensation for the treatment. The German market for headache is the best developed in Europe, by far. Generally, a migraine patient has very good access to structured care and specialists”, says Anders Weilandt.

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy